Inactive Instrument

Achillion Pharmaceuticals, Inc.

Equities

US00448Q2012

Biotechnology & Medical Research

Achillion Pharmaceuticals, Inc. : Achillion to Present at the Noble Financial Capital Markets' Ninth Annual Equity Conference

January 17, 2013 at 03:08 pm

MarketScreener.com By

NEW HAVEN, Conn., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial Officer of Achillion, will present a corporate update at the upcoming Noble Financial Capital Markets' Ninth Annual Equity Conference on Wednesday, January 23, 2013 at 9:30 a.m. EST at the Hard Rock Hotel in Hollywood, FL.

The live audio and video broadcast and the subsequent archived webcasts of the Company's presentations will be available on the Company's website, http://www.achillion.com, under the "News Center" section. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including the hepatitis C virus (HCV) and resistant bacterial infections.www.achillion.com or call 1-203-624-7000.


CONTACT: Company Contact:

         Glenn Schulman

         Achillion Pharmaceuticals, Inc.

         Tel. (203) 752-5510

         gschulman@achillion.com

         

         Investors:

         Mary Kay Fenton

         Achillion Pharmaceuticals, Inc.

         Tel. (203) 624-7000

         mfenton@achillion.com

distributed by

Latest news about Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from S&P Global BMI Index	29/01/20	CI
Achillion Pharmaceuticals, Inc.(NasdaqGM:ACHN) dropped from S&P TMI Index	29/01/20	CI
Achillion Pharmaceuticals, Inc.(NasdaqGM:ACHN) dropped from S&P Biotechnology Select Industry Index	29/01/20	CI
Achillion Pharmaceuticals, Inc. Announces Management Changes	28/01/20	CI
Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from NASDAQ Composite Index	28/01/20	CI
Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from NASDAQ Biotechnology Index	28/01/20	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of Achillion Pharmaceuticals, Inc..	27/01/20	CI
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting	09/12/19	CI
European Medicines Agency Grants Achillion PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor	19/11/19	CI
Achillion Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application for ACH-5228	11/11/19	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	07/11/19	CI
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. for approximately $880 million.	15/10/19	CI
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria	25/09/19	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	08/08/19	CI
Achillion Pharmaceuticals, Inc.'s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers	22/07/19	CI
Achillion Pharmaceuticals, Inc. Announces the Final Data Set for ACH-4471 (Newly Designated “Danicopan”) Proof of Concept Phase 2 Trial in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria	10/06/19	CI
Transcript : Achillion Pharmaceuticals, Inc. - Shareholder/Analyst Call	30/05/19
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting	17/05/19	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	09/05/19	CI
Achillion Pharmaceuticals Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy	03/04/19	CI
Achillion Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 PNH Combination Trial	27/03/19	CI
Transcript : Achillion Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Conference 2019, Mar-14-2019 10:15 AM	14/03/19
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	07/03/19	CI
Achillion Pharmaceuticals, Inc. Announces Expansion into a Second Office in Blue Bell, Philadelphia	21/02/19	CI
Achillion Pharmaceuticals, Inc. Announces Management Changes, Effective as of February 11, 2019	11/02/19	CI

Chart Achillion Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs